{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:18:26Z","timestamp":1780341506966,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00702-017-1810-z","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T07:54:15Z","timestamp":1510732455000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Fluid biomarker agreement and interrelation in dementia due to Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"125","author":[{"name":"For the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-6365","authenticated-orcid":false,"given":"Panagiotis","family":"Alexopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Roesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Werle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Thierjung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iliana","family":"Lentzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Ortner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Laskaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippos","family":"Gourzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"issue":"1","key":"1810_CR1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frolich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B (2017) On the path to 2025. Understanding the Alzheimer\u2019s disease continuum. Alzheimer\u2019s Res Ther 9(1):60","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"2","key":"1810_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-122329","volume":"36","author":"P Alexopoulos","year":"2013","unstructured":"Alexopoulos P, Guo L-H, Jiang M, Bujo H, Grimmer T, Forster S, Drzezga A, Kurz A, Perneczky R (2013) Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer\u2019s disease cerebral metabolic signature. J Alzheimer\u2019s Dis 36(2):401\u2013408","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"6","key":"1810_CR3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jalz.2014.03.006","volume":"10","author":"P Alexopoulos","year":"2014","unstructured":"Alexopoulos P, Kriett L, Haller B, Klupp E, Gray K, Grimmer T, Laskaris N, Forster S, Perneczky R, Kurz A, Drzezga A, Fellgiebel A, Yakushev I (2014) Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 10(6):684\u2013689","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"7","key":"1810_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00406-015-0628-7","volume":"266","author":"P Alexopoulos","year":"2016","unstructured":"Alexopoulos P, Roesler J, Thierjung N, Werle L, Buck D, Yakushev I, Gleixner L, Kagerbauer S, Ortner M, Grimmer T, Kubler H, Martin J, Laskaris N, Kurz A, Perneczky R (2016) Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci 266(7):587\u2013597","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"1810_CR5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jalz.2014.05.1754","volume":"11","author":"D Bertens","year":"2015","unstructured":"Bertens D, Knol DL, Scheltens P, Visser PJ (2015) Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 11(5):511\u2013522","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"4","key":"1810_CR6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s13760-014-0423-7","volume":"115","author":"J-C Bier","year":"2015","unstructured":"Bier J-C, Verschraegen J, Vandenberghe R, Guillaume B, Picard G, Otte G, Mormont E, Gilles C, Segers K, Sieben A, Thiery E, Ventura M, de Deyn P, Deryck O, Versijpt J, Salmon E, Engelborghs S, Ivanoiu A (2015) Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer\u2019s disease. A BeDeCo survey. Acta Neurol Belg 115(4):547\u2013555","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"1810_CR7","first-page":"195.e1","volume":"11","author":"M Bocchetta","year":"2015","unstructured":"Bocchetta M, Galluzzi S, Kehoe PG, Aguera E, Bernabei R, Bullock R, Ceccaldi M, Dartigues J-F, de Mendonca A, Didic M, Eriksdotter M, Felician O, Frolich L, Gertz H-J, Hallikainen M, Hasselbalch SG, Hausner L, Heuser I, Jessen F, Jones RW, Kurz A, Lawlor B, Lleo A, Martinez-Lage P, Mecocci P, Mehrabian S, Monsch A, Nobili F, Nordberg A, Rikkert MO, Orgogozo J-M, Pasquier F, Peters O, Salmon E, Sanchez-Castellano C, Santana I, Sarazin M, Traykov L, Tsolaki M, Visser PJ, Wallin AK, Wilcock G, Wilkinson D, Wolf H, Yener G, Zekry D, Frisoni GB (2015) The use of biomarkers for the etiologic diagnosis of MCI in Europe. An EADC survey. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 11(2):195.e1\u2013206.e1","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"3","key":"1810_CR8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.23964","volume":"74","author":"PA Boyle","year":"2013","unstructured":"Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA, Bennett DA (2013) Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol 74(3):478\u2013489","journal-title":"Ann Neurol"},{"issue":"6","key":"1810_CR9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jalz.2016.09.015","volume":"13","author":"WD Brenowitz","year":"2017","unstructured":"Brenowitz WD, Hubbard RA, Keene CD, Hawes SE, Longstreth WT Jr, Woltjer RL, Kukull WA (2017) Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 13(6):654\u2013662","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"6","key":"1810_CR10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease. The IWG-2 criteria. Lancet Neurol 13(6):614\u2013629","journal-title":"Lancet Neurol"},{"issue":"1","key":"1810_CR11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13195-015-0114-5","volume":"7","author":"J Dumurgier","year":"2015","unstructured":"Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche J-L, Peoc\u2019h K, Sablonniere B, Kastanenka KV, Delaby C, Pasquier F, Touchon J, Hugon J, Paquet C, Lehmann S (2015) Cerebrospinal fluid amyloid-beta 42\/40 ratio in clinical setting of memory centers. A multicentric study. Alzheimer\u2019s Res Ther 7(1):30","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"3","key":"1810_CR12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3):512\u2013519","journal-title":"Ann Neurol"},{"key":"1810_CR13","volume-title":"Wiley series in probability and statistics","author":"JL Fleiss","year":"2003","unstructured":"Fleiss JL, Levin BA, Paik MC (2003) Statistical methods for rates and proportions. In: Fleiss JL, Levin B, Paik MC (eds) Wiley series in probability and statistics, 3rd edn. Wiley, Hoboken","edition":"3"},{"key":"1810_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-4-13","volume":"4","author":"TF Gendron","year":"2009","unstructured":"Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegener 4:13","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1810_CR15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jalz.2012.10.002","volume":"9","author":"L-H Guo","year":"2013","unstructured":"Guo L-H, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R (2013) Brain size and the compensation of Alzheimer\u2019s disease symptoms. A longitudinal cohort study. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 9(5):580\u2013586","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"3","key":"1810_CR16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jalz.2016.09.009","volume":"13","author":"S-K Herukka","year":"2017","unstructured":"Herukka S-K, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczynska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G (2017) Recommendations for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 13(3):285\u2013295","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"8","key":"1810_CR17","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, de Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52(8):1555\u20131562","journal-title":"Neurology"},{"key":"1810_CR18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuroimage.2017.02.058","volume":"152","author":"Y Iturria-Medina","year":"2017","unstructured":"Iturria-Medina Y, Carbonell FM, Sotero RC, Chouinard-Decorte F, Evans AC (2017) Multifactorial causal model of brain (dis)organization and therapeutic intervention. Application to Alzheimer\u2019s disease. NeuroImage 152:60\u201377","journal-title":"NeuroImage"},{"issue":"2","key":"1810_CR19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer\u2019s disease. An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2):207\u2013216","journal-title":"Lancet Neurol"},{"issue":"15","key":"1810_CR20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA (2009) Relationships between biomarkers in aging and dementia. Neurology 73(15):1193\u20131199","journal-title":"Neurology"},{"issue":"1","key":"1810_CR21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.0b013e318204a397","volume":"76","author":"S Kim","year":"2011","unstructured":"Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ (2011) Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76(1):69\u201379","journal-title":"Neurology"},{"issue":"10","key":"1810_CR22","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00702-013-1060-7","volume":"120","author":"AD Korczyn","year":"2013","unstructured":"Korczyn AD (2013) Is Alzheimer\u2019s disease a homogeneous disease entity? J Neural Transm (Vienna Austria) 120(10):1475\u20131477","journal-title":"J Neural Transm (Vienna Austria)"},{"issue":"3","key":"1810_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.0b013e3181e8e8b8","volume":"75","author":"SM Landau","year":"2010","unstructured":"Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75(3):230\u2013238","journal-title":"Neurology"},{"issue":"6","key":"1810_CR24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ (2013) Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 74(6):826\u2013836","journal-title":"Ann Neurol"},{"issue":"3","key":"1810_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/alzrt267","volume":"6","author":"S Lehmann","year":"2014","unstructured":"Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, Bombois S, Bousiges O, Campion D, Cretin B, Delaby C, Hannequin D, Jung B, Hugon J, Laplanche J-L, Miguet-Alfonsi C, Peoc\u2019h K, Philippi N, Quillard-Muraine M, Sablonniere B, Touchon J, Vercruysse O, Paquet C, Pasquier F, Gabelle A (2014) A diagnostic scale for Alzheimer\u2019s disease based on cerebrospinal fluid biomarker profiles. Alzheimer\u2019s Res Ther 6(3):38","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"4","key":"1810_CR26","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-142952","volume":"45","author":"A Leuzy","year":"2015","unstructured":"Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A (2015) Concordance and diagnostic accuracy of 11CPIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 45(4):1077\u20131088","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"Pt 9","key":"1810_CR27","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/aww160","volume":"139","author":"A Leuzy","year":"2016","unstructured":"Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, Lleo A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CAF, Beer A, Blesa R, Fortea J, Herukka S-K, Portelius E, Pannee J, Zetterberg H, Blennow K, Nordberg A (2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain J Neurol 139(Pt 9):2540\u20132553","journal-title":"Brain J Neurol"},{"key":"1810_CR28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuint.2017.05.010","volume":"108","author":"S Lista","year":"2017","unstructured":"Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Dos Santos AM, Epelbaum S, Lamari F, Dubois B, Floris R, Garaci F, Hampel H (2017) Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer\u2019s disease. Neurochem Int 108:355\u2013360","journal-title":"Neurochem Int"},{"issue":"7662","key":"1810_CR29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/547153a","volume":"547","author":"E McDade","year":"2017","unstructured":"McDade E, Bateman RJ (2017) Stop Alzheimer\u2019s before it starts. Nature 547(7662):153\u2013155","journal-title":"Nature"},{"issue":"7","key":"1810_CR30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34(7):939\u2013944","journal-title":"Neurology"},{"issue":"3","key":"1810_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer\u2019s disease. Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 7(3):263\u2013269","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"6","key":"1810_CR32","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jalz.2014.03.003","volume":"10","author":"JL Molinuevo","year":"2014","unstructured":"Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis. A consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative. Alzheimer\u2019s Dement J Alzheimer\u2019s Association 10(6):808\u2013817","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Association"},{"issue":"2","key":"1810_CR33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3233\/JAD-150738","volume":"56","author":"T Persson","year":"2017","unstructured":"Persson T, Lattanzio F, Calvo-Garrido J, Rimondini R, Rubio-Rodrigo M, Sundstrom E, Maioli S, Sandebring-Matton A, Cedazo-Minguez A (2017) Apolipoprotein E4 elicits lysosomal cathepsin D release, decreased thioredoxin-1 levels, and apoptosis. J Alzheimer\u2019s Dis 56(2):601\u2013617","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"6","key":"1810_CR34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21037\/atm.2016.03.05","volume":"4","author":"C Reitz","year":"2016","unstructured":"Reitz C (2016) Toward precision medicine in Alzheimer\u2019s disease. Annals of translational medicine 4(6):107","journal-title":"Annals of translational medicine"},{"issue":"1","key":"1810_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12031-011-9665-5","volume":"47","author":"H Rosenmann","year":"2012","unstructured":"Rosenmann H (2012) CSF biomarkers for amyloid and tau pathology in Alzheimer\u2019s disease. J Mol Neurosci 47(1):1\u201314","journal-title":"J Mol Neurosci"},{"issue":"3","key":"1810_CR36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jalz.2010.03.013","volume":"6","author":"AJ Saykin","year":"2010","unstructured":"Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, Risacher SL, Nho K, Huentelman MJ, Craig DW, Thompson PM, Stein JL, Moore JH, Farrer LA, Green RC, Bertram L, Jack CR, Weiner MW (2010) Alzheimer\u2019s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes. Genetics core aims, progress, and plans. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 6(3):265\u2013273","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"3","key":"1810_CR37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000449410","volume":"6","author":"M Schjonning Nielsen","year":"2016","unstructured":"Schjonning Nielsen M, Simonsen AH, Siersma V, Hasselbalch SG, Hogh P (2016) Are CSF biomarkers useful as prognostic indicators in diagnostically unresolved cognitively impaired patients in a normal clinical setting. Dement Geriatr Cogn Disord Extra 6(3):465\u2013476","journal-title":"Dement Geriatr Cogn Disord Extra"},{"issue":"1","key":"1810_CR38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","volume":"78","author":"NSM Schoonenboom","year":"2012","unstructured":"Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YAL, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78(1):47\u201354","journal-title":"Neurology"},{"issue":"4","key":"1810_CR39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM-Y, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol 65(4):403\u2013413","journal-title":"Ann Neurol"},{"issue":"3","key":"1810_CR40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jalz.2016.09.008","volume":"13","author":"AH Simonsen","year":"2017","unstructured":"Simonsen AH, Herukka S-K, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczynska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G (2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 13(3):274\u2013284","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"Pt 9","key":"1810_CR41","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillback","year":"2015","unstructured":"Skillback T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, Blennow K, Eriksdotter M, Zetterberg H (2015) Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain J Neurol 138(Pt 9):2716\u20132731","journal-title":"Brain J Neurol"},{"issue":"6","key":"1810_CR42","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1214\/009053607000000505","volume":"35","author":"GJ Sz\u00e9kely","year":"2007","unstructured":"Sz\u00e9kely GJ, Rizzo ML, Bakirov NK (2007) Measuring and testing dependence by correlation of distances. Ann Stat 35(6):2769\u20132794","journal-title":"Ann Stat"},{"issue":"5","key":"1810_CR43","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/j.1471-4159.1993.tb09823.x","volume":"61","author":"M Vandermeeren","year":"1993","unstructured":"Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P (1993) Detection of tau proteins in normal and Alzheimer\u2019s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61(5):1828\u20131834","journal-title":"J Neurochem"},{"issue":"4","key":"1810_CR44","first-page":"245","volume":"7","author":"H Vanderstichele","year":"2000","unstructured":"Vanderstichele H, van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid Int J Exp Clin Investig 7(4):245\u2013258","journal-title":"Amyloid Int J Exp Clin Investig"},{"issue":"4","key":"1810_CR45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease. A prospective cohort study. Lancet Neurol 12(4):357\u2013367","journal-title":"Lancet Neurol"},{"issue":"3","key":"1810_CR46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000090631","volume":"21","author":"AK Wallin","year":"2006","unstructured":"Wallin AK, Blennow K, Andreasen N, Minthon L (2006) CSF biomarkers for Alzheimer\u2019s Disease. Levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 21(3):131\u2013138","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"1810_CR47","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2016.11.007","volume":"13","author":"MW Weiner","year":"2017","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ (2017) Recent publications from the Alzheimer\u2019s disease neuroimaging initiative. Reviewing progress toward improved AD clinical trials. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 13(4):e1\u2013e85","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"8750","key":"1810_CR48","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/0140-6736(91)92823-K","volume":"337","author":"PR Wenham","year":"1991","unstructured":"Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet (Lond, Engl) 337(8750):1158\u20131159","journal-title":"Lancet (Lond, Engl)"},{"issue":"2","key":"1810_CR49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/156720512799361592","volume":"9","author":"I Yakushev","year":"2012","unstructured":"Yakushev I, Muller MJ, Buchholz H-G, Lang U, Rossmann H, Hampel H, Schreckenberger M, Fellgiebel A (2012) Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer\u2019s disease. Curr Alzheimer Res 9(2):241\u2013247","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"1810_CR50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","volume":"30","author":"Y Yamazaki","year":"2016","unstructured":"Yamazaki Y, Painter MM, Bu G, Kanekiyo T (2016) Apolipoprotein E as a therapeutic target in Alzheimer\u2019s disease. A review of basic research and clinical evidence. CNS Drugs 30(9):773\u2013789","journal-title":"CNS Drugs"},{"issue":"1","key":"1810_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neuron.2017.09.003","volume":"96","author":"N Zhao","year":"2017","unstructured":"Zhao N, Liu C-C, Qiao W, Bu G (2017) Apolipoprotein E, receptors, and modulation of Alzheimer\u2019s disease. Neuron 96(1):115\u2013129.e5. https:\/\/doi.org\/10.1016\/j.neuron.2017.09.003","journal-title":"Neuron"},{"issue":"9","key":"1810_CR52","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/clinchem\/43.9.1657","volume":"43","author":"A Zivelin","year":"1997","unstructured":"Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U (1997) Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 43(9):1657\u20131659","journal-title":"Clin Chem"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-017-1810-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1810-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1810-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T21:41:39Z","timestamp":1603316499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-017-1810-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1007\/s00702-017-1810-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}